N A H Seneadza1, S Antwi2, H Yang3, A Enimil2, A Dompreh4, L Wiesner5, C A Peloquin6, M Lartey7, M Lauzardo8, A Kwara8. 1. Department of Epidemiology, University of Florida, Gainesville, FL, USA, Department of Community Health, University of Ghana Medical School, Kumasi, Ghana. 2. Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana, Department of Child Health, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. 3. Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA. 4. Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana. 5. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. 6. Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA. 7. Department of Medicine and Therapeutics, University of Ghana Medical School, Accra, Ghana, Fevers Unit, Korle Bu Teaching Hospital, Accra, Ghana. 8. Division of Infectious Diseases and Global Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
Abstract
BACKGROUND: Anti-TB drugs dosing based on weight alone may contribute to suboptimal drug concentrations and poor treatment outcomes in malnourished children. We examined the effect of malnutrition on the pharmacokinetics (PK) of first-line anti-TB drugs in children. METHODS: Drug concentrations were measured in Ghanaian children during the intensive phase of TB treatment. Weight-for-age (WFA), height-for-age (HFA), weight-for-height (WFH) and body mass index-for-age (BFA) were calculated and children with Z-scores < -2 SD (standard deviations) were considered as having malnutrition. PK differences of anti-TB drugs were compared by nutritional status. RESULTS: Of 100 participants, 24/48 (50.0%) of those younger than 5 years had wasting, 58/86 (67.4%) were underweight, and 56/99 (56.6%) had stunting; 22/51 (43.1%) children aged ≥5 years had low BFA. Children with stunting were more likely than controls to have lower mean peak concentration (Cmax) and area under the curve (AUC0-8h) of rifampin (RIF) and pyrazinamide (PZA), as well as a higher frequency of Cmax below the normal range. Wasting and underweight were associated with lower mean ethambutol (EMB) Cmax and AUC0-8h. CONCLUSIONS: The current WHO-recommended dosages were associated with lower plasma exposure of RIF, PZA and EMB in children with stunting, wasting and underweight. Anti-TB drugs dosing models for children may need to include height.
BACKGROUND: Anti-TB drugs dosing based on weight alone may contribute to suboptimal drug concentrations and poor treatment outcomes in malnourished children. We examined the effect of malnutrition on the pharmacokinetics (PK) of first-line anti-TB drugs in children. METHODS: Drug concentrations were measured in Ghanaian children during the intensive phase of TB treatment. Weight-for-age (WFA), height-for-age (HFA), weight-for-height (WFH) and body mass index-for-age (BFA) were calculated and children with Z-scores < -2 SD (standard deviations) were considered as having malnutrition. PK differences of anti-TB drugs were compared by nutritional status. RESULTS: Of 100 participants, 24/48 (50.0%) of those younger than 5 years had wasting, 58/86 (67.4%) were underweight, and 56/99 (56.6%) had stunting; 22/51 (43.1%) children aged ≥5 years had low BFA. Children with stunting were more likely than controls to have lower mean peak concentration (Cmax) and area under the curve (AUC0-8h) of rifampin (RIF) and pyrazinamide (PZA), as well as a higher frequency of Cmax below the normal range. Wasting and underweight were associated with lower mean ethambutol (EMB) Cmax and AUC0-8h. CONCLUSIONS: The current WHO-recommended dosages were associated with lower plasma exposure of RIF, PZA and EMB in children with stunting, wasting and underweight. Anti-TB drugs dosing models for children may need to include height.
Authors: R M Hicks; N Padayatchi; N S Shah; A Wolf; L Werner; V B Sunkari; M R O'Donnell Journal: Int J Tuberc Lung Dis Date: 2014-09 Impact factor: 2.373
Authors: S Thee; J A Seddon; P R Donald; H I Seifart; C J Werely; A C Hesseling; B Rosenkranz; S Roll; K Magdorf; H S Schaaf Journal: Antimicrob Agents Chemother Date: 2011-10-03 Impact factor: 5.191
Authors: Gregory L Kearns; Susan M Abdel-Rahman; Sarah W Alander; Douglas L Blowey; J Steven Leeder; Ralph E Kauffman Journal: N Engl J Med Date: 2003-09-18 Impact factor: 91.245
Authors: Mary Glover-Amengor; Isaac Agbemafle; Lynda Larmkie Hagan; Frank Peget Mboom; Gladys Gamor; Asamoah Larbi; Irmgard Hoeschle-Zeledon Journal: Arch Public Health Date: 2016-04-04
Authors: Bryan J Vonasek; Kendra K Radtke; Paula Vaz; W Chris Buck; Chishala Chabala; Eric D McCollum; Olivier Marcy; Elizabeth Fitzgerald; Alexander Kondwani; Anthony J Garcia-Prats Journal: Expert Rev Respir Med Date: 2022-02-28 Impact factor: 4.300
Authors: J W C Alffenaar; S L Stocker; L Davies Forsman; A Garcia-Prats; S K Heysell; R E Aarnoutse; O W Akkerman; A Aleksa; R van Altena; W Arrazola de Oñata; P K Bhavani; N Van't Boveneind-Vrubleuskaya; A C C Carvalho; R Centis; J M Chakaya; D M Cirillo; J G Cho; L D Ambrosio; M P Dalcolmo; P Denti; K Dheda; G J Fox; A C Hesseling; H Y Kim; C U Köser; B J Marais; I Margineanu; A G Märtson; M Munoz Torrico; H M Nataprawira; C W M Ong; R Otto-Knapp; C A Peloquin; D R Silva; R Ruslami; P Santoso; R M Savic; R Singla; E M Svensson; A Skrahina; D van Soolingen; S Srivastava; M Tadolini; S Tiberi; T A Thomas; Z F Udwadia; D H Vu; W Zhang; S G Mpagama; T Schön; G B Migliori Journal: Int J Tuberc Lung Dis Date: 2022-06-01 Impact factor: 3.427
Authors: Kendra K Radtke; Anneke C Hesseling; J L Winckler; Heather R Draper; Belen P Solans; Stephanie Thee; Lubbe Wiesner; Louvina E van der Laan; Barend Fourie; James Nielsen; H Simon Schaaf; Radojka M Savic; Anthony J Garcia-Prats Journal: Clin Infect Dis Date: 2022-04-28 Impact factor: 20.999